Phase II study of amonafide in gastric adenocarcinoma - Illinois Cancer Center trial

Michael R. Mullane*, Richard L. Schilsky, Rosemary B. Carroll, James L. Wade, Lary J. Kilton, Richard R. Blough, Anne Bauman, Suzanne L. French, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered daily for 5 consecutive days every 3 weeks at a starting dose of 300 mg/m2/d. Doses were modified according to the grade of toxicity experienced and eight patients underwent dose escalations. All 12 patients were evaluable for response and toxicities were predominantly hematologic. Stabilization of disease for at least 28 days was observed in seven patients and disease progression was noted in five. The median survival was 7.4 months. Doses were sufficient to produce severe bone marrow toxicity in one-third of the patients treated. None of the patients responded to therapy, implying a true response rate less than.221. Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule.

Original languageEnglish (US)
Pages (from-to)267-270
Number of pages4
JournalInvestigational New Drugs
Volume12
Issue number3
DOIs
StatePublished - Sep 1 1994

Fingerprint

amonafide
Stomach
Adenocarcinoma
Neoplasms
Intercalating Agents
Disease Progression
Appointments and Schedules
Bone Marrow

Keywords

  • amonafide (nafidimine)
  • gastric adenocarcinoma
  • phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Mullane, Michael R. ; Schilsky, Richard L. ; Carroll, Rosemary B. ; Wade, James L. ; Kilton, Lary J. ; Blough, Richard R. ; Bauman, Anne ; French, Suzanne L. ; Benson, Al B. / Phase II study of amonafide in gastric adenocarcinoma - Illinois Cancer Center trial. In: Investigational New Drugs. 1994 ; Vol. 12, No. 3. pp. 267-270.
@article{81468d0eb937466a98781f25ff6e7676,
title = "Phase II study of amonafide in gastric adenocarcinoma - Illinois Cancer Center trial",
abstract = "Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered daily for 5 consecutive days every 3 weeks at a starting dose of 300 mg/m2/d. Doses were modified according to the grade of toxicity experienced and eight patients underwent dose escalations. All 12 patients were evaluable for response and toxicities were predominantly hematologic. Stabilization of disease for at least 28 days was observed in seven patients and disease progression was noted in five. The median survival was 7.4 months. Doses were sufficient to produce severe bone marrow toxicity in one-third of the patients treated. None of the patients responded to therapy, implying a true response rate less than.221. Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule.",
keywords = "amonafide (nafidimine), gastric adenocarcinoma, phase II trial",
author = "Mullane, {Michael R.} and Schilsky, {Richard L.} and Carroll, {Rosemary B.} and Wade, {James L.} and Kilton, {Lary J.} and Blough, {Richard R.} and Anne Bauman and French, {Suzanne L.} and Benson, {Al B.}",
year = "1994",
month = "9",
day = "1",
doi = "10.1007/BF00873971",
language = "English (US)",
volume = "12",
pages = "267--270",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Mullane, MR, Schilsky, RL, Carroll, RB, Wade, JL, Kilton, LJ, Blough, RR, Bauman, A, French, SL & Benson, AB 1994, 'Phase II study of amonafide in gastric adenocarcinoma - Illinois Cancer Center trial', Investigational New Drugs, vol. 12, no. 3, pp. 267-270. https://doi.org/10.1007/BF00873971

Phase II study of amonafide in gastric adenocarcinoma - Illinois Cancer Center trial. / Mullane, Michael R.; Schilsky, Richard L.; Carroll, Rosemary B.; Wade, James L.; Kilton, Lary J.; Blough, Richard R.; Bauman, Anne; French, Suzanne L.; Benson, Al B.

In: Investigational New Drugs, Vol. 12, No. 3, 01.09.1994, p. 267-270.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II study of amonafide in gastric adenocarcinoma - Illinois Cancer Center trial

AU - Mullane, Michael R.

AU - Schilsky, Richard L.

AU - Carroll, Rosemary B.

AU - Wade, James L.

AU - Kilton, Lary J.

AU - Blough, Richard R.

AU - Bauman, Anne

AU - French, Suzanne L.

AU - Benson, Al B.

PY - 1994/9/1

Y1 - 1994/9/1

N2 - Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered daily for 5 consecutive days every 3 weeks at a starting dose of 300 mg/m2/d. Doses were modified according to the grade of toxicity experienced and eight patients underwent dose escalations. All 12 patients were evaluable for response and toxicities were predominantly hematologic. Stabilization of disease for at least 28 days was observed in seven patients and disease progression was noted in five. The median survival was 7.4 months. Doses were sufficient to produce severe bone marrow toxicity in one-third of the patients treated. None of the patients responded to therapy, implying a true response rate less than.221. Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule.

AB - Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator. Treatment consisted of a 60-minute infusion of amonafide which was administered daily for 5 consecutive days every 3 weeks at a starting dose of 300 mg/m2/d. Doses were modified according to the grade of toxicity experienced and eight patients underwent dose escalations. All 12 patients were evaluable for response and toxicities were predominantly hematologic. Stabilization of disease for at least 28 days was observed in seven patients and disease progression was noted in five. The median survival was 7.4 months. Doses were sufficient to produce severe bone marrow toxicity in one-third of the patients treated. None of the patients responded to therapy, implying a true response rate less than.221. Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule.

KW - amonafide (nafidimine)

KW - gastric adenocarcinoma

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0028149881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028149881&partnerID=8YFLogxK

U2 - 10.1007/BF00873971

DO - 10.1007/BF00873971

M3 - Article

C2 - 7896548

AN - SCOPUS:0028149881

VL - 12

SP - 267

EP - 270

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -